Matthew L Carlson1,2, Alexander P Marston1, Amy E Glasgow3, Elizabeth B Habermann3, Alex D Sweeney4, Michael J Link1,2, George B Wanna5. 1. Department of Otorhinolaryngology, Mayo Clinic School of Medicine, Rochester, Minnesota. 2. Department of Neurologic Surgery, Mayo Clinic School of Medicine, Rochester, Minnesota. 3. Division of Health Care Policy and Research and the Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic School of Medicine, Rochester, Minnesota. 4. Bobby R. Alford Department of Otolaryngology-Head and Neck Surgery, Baylor College of Medicine, Houston, Texas. 5. Department of Otolaryngology-Head and Neck Surgery, Vanderbilt University, Nashville, Tennessee, U.S.A.
Abstract
OBJECTIVES/HYPOTHESIS: To estimate the impact of race on disease presentation and treatment of vestibular schwannoma (VS) in the United States. STUDY DESIGN: Analysis of a national population-based tumor registry. METHODS: Analysis of the Surveillance, Epidemiology, and End Results database was performed, including all patients identified with a diagnosis of VS. Associations between race, disease presentation, treatment strategy, and overall survival were analyzed in a univariate and multivariable model. RESULTS: A total of 9,782 patients with VS were identified among 822 million person-years. Of these, 7,400 (75.6%) claimed white, 807 (8.2%) Hispanic, 755 (7.7%) Asian, 397 (4.1%) black, and 423 (4.3%) patients reported other race. The median annual incidence of disease was lowest among black (0.43 per 100,000 persons) and Hispanic populations (0.45 per 100,000 persons) and highest among white (1.61 per 100,000 persons) populations (P < 0.001). Overall, Hispanic patients were diagnosed at the youngest age, and white patients were diagnosed at the oldest age (mean of 50.0 vs. 56.0 years, respectively; P < 0.001). Compared to white populations, black, Hispanic, and Asian populations were more likely to present with larger tumors (P < 0.001). After controlling for tumor size, age, and treatment center in a multivariable model, Hispanic patients were more likely than white patients to undergo surgery (P = 0.010); however, there were no differences between white, black, and Asian populations with regard to treatment modality. Hispanic and black patients had the poorest overall survival following surgery compared to other groups. CONCLUSION: Racial differences among patients with VS exist within the United States. Further studies are required to determine which factors drive differences in tumor size, age, annual disease incidence, and overall survival between races. LEVEL OF EVIDENCE: 3. Laryngoscope, 126:2128-2133, 2016.
OBJECTIVES/HYPOTHESIS: To estimate the impact of race on disease presentation and treatment of vestibular schwannoma (VS) in the United States. STUDY DESIGN: Analysis of a national population-based tumor registry. METHODS: Analysis of the Surveillance, Epidemiology, and End Results database was performed, including all patients identified with a diagnosis of VS. Associations between race, disease presentation, treatment strategy, and overall survival were analyzed in a univariate and multivariable model. RESULTS: A total of 9,782 patients with VS were identified among 822 million person-years. Of these, 7,400 (75.6%) claimed white, 807 (8.2%) Hispanic, 755 (7.7%) Asian, 397 (4.1%) black, and 423 (4.3%) patients reported other race. The median annual incidence of disease was lowest among black (0.43 per 100,000 persons) and Hispanic populations (0.45 per 100,000 persons) and highest among white (1.61 per 100,000 persons) populations (P < 0.001). Overall, Hispanic patients were diagnosed at the youngest age, and white patients were diagnosed at the oldest age (mean of 50.0 vs. 56.0 years, respectively; P < 0.001). Compared to white populations, black, Hispanic, and Asian populations were more likely to present with larger tumors (P < 0.001). After controlling for tumor size, age, and treatment center in a multivariable model, Hispanic patients were more likely than white patients to undergo surgery (P = 0.010); however, there were no differences between white, black, and Asian populations with regard to treatment modality. Hispanic and black patients had the poorest overall survival following surgery compared to other groups. CONCLUSION: Racial differences among patients with VS exist within the United States. Further studies are required to determine which factors drive differences in tumor size, age, annual disease incidence, and overall survival between races. LEVEL OF EVIDENCE: 3. Laryngoscope, 126:2128-2133, 2016.
Authors: Maria Peris-Celda; Christopher S Graffeo; Avital Perry; Panagiotis Kerezoudis; Nicole M Tombers; Matthew L Carlson; Michael J Link Journal: J Neurol Surg B Skull Base Date: 2018-10-09
Authors: Erin C Peckham-Gregory; Roberto E Montenegro; David A Stevenson; David H Viskochil; Michael E Scheurer; Philip J Lupo; Joshua D Schiffman Journal: J Neurooncol Date: 2018-04-16 Impact factor: 4.130
Authors: Jonathan L Hatch; Michael J Bauschard; Shaun A Nguyen; Paul R Lambert; Ted A Meyer; Theodore R McRackan Journal: Otolaryngol Head Neck Surg Date: 2018-03-27 Impact factor: 3.497
Authors: Roland Goldbrunner; Michael Weller; Jean Regis; Morten Lund-Johansen; Pantelis Stavrinou; David Reuss; D Gareth Evans; Florence Lefranc; Kita Sallabanda; Andrea Falini; Patrick Axon; Olivier Sterkers; Laura Fariselli; Wolfgang Wick; Joerg-Christian Tonn Journal: Neuro Oncol Date: 2020-01-11 Impact factor: 12.300
Authors: Deborah Ruth Smith; Heva Jasmine Saadatmand; Cheng-Chia Wu; Paul J Black; Yen-Ruh Wuu; Jeraldine Lesser; Maryellen Horan; Steven R Isaacson; Tony J C Wang; Michael B Sisti Journal: Neurosurgery Date: 2019-12-01 Impact factor: 4.654